HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Göril Karlsson Selected Research

siponimod

8/2023Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
9/2022Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
1/2022Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
1/2021Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
1/2021Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Göril Karlsson Research Topics

Disease

5Chronic Progressive Multiple Sclerosis
08/2023 - 01/2021
2Atrophy
08/2023 - 01/2022
1Demyelinating Diseases (Demyelinating Disease)
08/2023
1Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
08/2023
1Multiple Sclerosis
01/2021

Drug/Important Bio-Agent (IBA)

5siponimodIBA
08/2023 - 01/2021
1sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
08/2023
1Fingolimod Hydrochloride (FTY720)FDA Link
08/2023
1Sphingosine-1-Phosphate ReceptorsIBA
09/2022